CoChat

A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Goals of work Comparing antiemetic efficacy of different 5-HT(3)-receptor antagonists (5-HT(3)RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV).Patients and methods Comparisons between 5-HT(3)RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based).Main results When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6).Conclusions Efficacy of 5-HT(3)RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00520-006-0186-7

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Huc P, Block S, Carlier D et al (1998) Oral granisetron versus oral ondansetron for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapies. Bull Cancer (Paris) 85:562–568
  2. Mabro M, Kerbrat P (1999) Etude comparative du granisetron per os et de l’ondansetron IV chez des patientes recevant une chimiotherapie pour un cancer du sein. Bull Cancer (Paris) 86:295–301
  3. Massidda B, Laconi S, Foddi M et al (1994) Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT3 receptors. Ann Oncol 5:204
  4. Mendarte L, Aguas CM, Martinez BE et al (2000) Meta-analysis of granisetron versus ondansetron: efficacy and safety in the prevention of acute emesis induced by high dose cisplatin containing schedules. Med Clin (Barcelona) 115:456–460
  5. Monde M, Grazie M, De Vita F et al (1994) Tropisetron vs granisetron nell’emesi acuta e ri-tardata indotta da cis-platino: dati preliminary. Tumori 80:150 (Abstr 428)
  6. Multinational Association for Supportive Care in Cancer (2005) Antiemetic guidelines from the Consensus Conference on Antiemetic Therapy. Perugia International Cancer Conference VII. Perugia, Italy; 29–31 March 2004. Support Care Cancer 13:77–79; 80–84; 85–96; 97–103; 104–108; 109–111; 112–116; 117–121; 122–128; 129–131

Cited by

See all 93

Metadata

Authors
Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J.
Affiliations
  • Martin Luther University Halle-Wittenberg (DE)
  • WiSP Wissenschaftlicher Service Pharma GmbH (Germany) (DE)
  • Mayo Clinic (US)
Corresponding author
Jordan, K.
Venue
Supportive Care in Cancer
Published
2007-01-05
Volume
15
Issue
9
Pages
1023-1033
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W2013631853
Cited by
93
References
71
Citations by year
2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7 · 2013: 7 · 2012: 10
FWCI
1.28
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Supportive Care in Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords
5-HT3 receptor antagonists, chemotherapy-induced nausea and vomiting, antiemetic efficacy, granisetron, ondansetron, tropisetron, dolasetron, cisplatin-based chemotherapy, drug dose comparison, drug efficacy comparison
MeSH terms
Tropisetron, Antiemetics, Antineoplastic Agents, Humans, Indoles, Quinolizines, Serotonin Antagonists, Vomiting, Treatment Outcome, Ondansetron, Granisetron, Serotonin 5-HT3 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.